Celltrion achieves export declaration record of KRW 600 billion with Remsima
The last year’s export declaration record of ‘Remsima(rheumatoid arthritis treatment),’ a Celltrion’s biosimilar, was observed to be KRW 600 billion increased by approximately 5 times higher than the record of the year before.
The Remsima’s export declaration record of 2015 was aggregated at USD...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
